Chronic atrophic gastritis as a precancer: the evolution of ideas from the Sydney consensus to Maastricht VI




chronic atrophic gastritis, H. pylori, metaplasia, dysplasia, cancer, precancer


Aim. The purpose of the work is the evolution of systems and classifications of gastritis: Sydney Consensus (1990), Houston Modification (1994), OLGA/OLGIM (2008), Kyoto (2014), MAPS II (2019), Maastricht IV (2022).

Materials and methods. During the work, 25 sources of information were used.

Results. Chronic atrophic gastritis (ChAG) is a clinical and morphological diagnosis, and the presented clinical forms (types) of gastritis have characteristic morphological criteria. According to the Sydney system, changes in the antrum and body of the stomach are described separately. This has led to a lack of clear risk stratification criteria for CG and also complicates the objective analysis of regression of inflammation and atrophy. OLGA/OLGIM systems were proposed to determine the stage of atrophy and IM. The authors of the Kyoto consensus add and clarify the etiological section of ChAG. In MAPS II, ChAG and IM are considered precancerous conditions, as they increase the risk of developing gastric cancer and are the background for the occurrence of dysplasia and adenocarcinoma. For patients with dysplasia and the absence of visible changes in the mucous membrane, high-resolution endoscopy with staining is recommended. They should be examined after 6 months for a high degree of dysplasia and after 12 months for a low degree of dysplasia. Patients with IM and one localization have a high risk of developing gastric cancer. However, the high risk does not give the right to follow up in the majority of cases when high-quality endoscopy with biopsy does not show severe atrophy. Patients with IM of one location, with a family history of cancer, or with incomplete IM and persistence of H. pylori chromo endoscopy with biopsy must be done once every 3 years. Patients with extended fields of atrophic aggression (pronounced atrophic changes) or IM in the antrum and body, OLGA/OLGIM III/IV should be screened with chromoendoscopy with biopsy every 3 years. Patients with significant atrophy and familial cancer benefit from chromoendoscopy and biopsy every 1–2 years after initial diagnosis. Patients with autoimmune gastritis are recommended to be screened every 3–5 years. According to Maastricht VI, H. pylori is the main etiological factor of gastric adenocarcinoma, including proximal gastric cancer.

Conclusions. After careful study and analysis, we came to the conclusion about the gradual development of the principles of evidence-based medicine in the issue of improving the clinical and morphological diagnosis of chronic atrophic gastritis as a precancerous of the stomach.


Author Biographies

Yu. M. Stepanov, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, PhD, DSc, Professor, Director, Corresponding member of the National Academy of Sciences of Ukraine

Yu. A. Haidar, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro

MD, PhD, DSc, Head of the Laboratory of Pathomorphology

O. A. Maltseva, SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine’, Dnipro

MD, Pathologist of the Laboratory of Pathomorphology


Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996). Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American journal of surgical pathology, 20(10), 1161-1181.

Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., Annibale, B., Dumonceau, J. M., Barros, R., Fléjou, J. F., Carneiro, F., van Hooft, J. E., Kuipers, E. J., & Dinis-Ribeiro, M. (2019). Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy, 51(4), 365-388.

Crafa, P., Russo, M., Miraglia, C., Barchi, A., Moccia, F., Nouvenne, A., Leandro, G., Meschi, T., De' Angelis, G. L., & Di Mario, F. (2018). From Sidney to OLGA: an overview of atrophic gastritis. Acta bio-medica : Atenei Parmensis, 89(8-S), 93-99.

Kim, H. W., Jeong, Y. J., Hwang, S. K., Park, Y. Y., Choi, Y. H., Kim, C. H., Magae, J., & Chang, Y. C. (2020). Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells. European journal of pharmacology, 880, 173199.

Mentis, A. A., Boziki, M., Grigoriadis, N., & Papavassiliou, A. G. (2019). Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cellular and molecular life sciences : CMLS, 76(13), 2477-2486.

Bychkov, M. A., & Yakhnytska, M. M. (2019). Hastroezofahealna refliuksna khvoroba: suchasnyi pohliad na problemu. Bukovynskyi medychnyi visnyk [Gastroesophageal reflux disease: a modern view on the problem]. Bukovynskyi medychnyi visnyk, 23(3),118-122.

Shibata, W., Sue, S., Tsumura, S., Ishii, Y., Sato, T., Kameta, E., Sugimori, M., Yamada, H., Kaneko, H., Sasaki, T., Ishii, T., Tamura, T., Kondo, M., & Maeda, S. (2017). Helicobacter-induced gastric inflammation alters the properties of gastric tissue stem/progenitor cells. BMC gastroenterology, 17(1), 145.

Alfarouk, K. O., Bashir, A. H. H., Aljarbou, A. N., Ramadan, A. M., Muddathir, A. K., AlHoufie, S. T. S., Hifny, A., Elhassan, G. O., Ibrahim, M. E., Alqahtani, S. S., AlSharari, S. D., Supuran, C. T., Rauch, C., Cardone, R. A., Reshkin, S. J., Fais, S., & Harguindey, S. (2019). The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management. Frontiers in oncology, 9, 75.

Rugge, M., Correa, P., Dixon, M. F., Fiocca, R., Hattori, T., Lechago, J., Leandro, G., Price, A. B., Sipponen, P., Solcia, E., Watanabe, H., & Genta, R. M. (2002). Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary pharmacology & therapeutics, 16(7), 1249-1259.

Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Chiriboga, L., Terinte, C., Pesci, A., Aviel-Ronen, S., Kiyokawa, T., Alvarado-Cabrero, I., Pike, M. C., Oliva, E., Park, K. J., & Soslow, R. A. (2018). Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas. The American journal of surgical pathology, 42(8), 989-1000.

Correa P. (1988). A human model of gastric carcinogenesis. Cancer research, 48(13), 3554-3560.

Fan, X., Yang, X. S., Bai, P., Ren, Y. B., Zhang, L., Li, X., Wang, L., Wang, Y., Ding, Y. M., Zeng, R. R., & Lin, X. C. (2020). Gastric adenocarcinoma of the fundic gland type: A case report. Medicine, 99(21), e20361.

Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325-1332.e7.

Rugge, M., Correa, P., Dixon, M. F., Hattori, T., Leandro, G., Lewin, K., Riddell, R. H., Sipponen, P., & Watanabe, H. (2000). Gastric dysplasia: the Padova international classification. The American journal of surgical pathology, 24(2), 167-176.

Schlemper, R. J., Riddell, R. H., Kato, Y., Borchard, F., Cooper, H. S., Dawsey, S. M., Dixon, M. F., Fenoglio-Preiser, C. M., Fléjou, J. F., Geboes, K., Hattori, T., Hirota, T., Itabashi, M., Iwafuchi, M., Iwashita, A., Kim, Y. I., Kirchner, T., Klimpfinger, M., Koike, M., Lauwers, G. Y., … Yamabe, H. (2000). The Vienna classification of gastrointestinal epithelial neoplasia. Gut, 47(2), 251-255.

Mosyichuk, L. M., Gaydar, Yu. A., Klenina, I. A., & Petishko, O. P. (2022). Morfofunktsionalni paraleli shlunka u khvorykh na khronichnyi atrofichnyi hastryt [Morphofunctional parallels of the stomach in patients with chronic atrophic gastritis]. Gastroenterologìa, 56(1), 1-7.

Rugge, M., Sugano, K., Scarpignato, C., Sacchi, D., Oblitas, W. J., & Naccarato, A. G. (2019). Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter, 24(2), e12571.

Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., Malfertheiner, P., & faculty members of Kyoto Global Consensus Conference (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64(9), 1353-1367.

Sugano, K., Spechler, S. J., El-Omar, E. M., McColl, K. E. L., Takubo, K., Gotoda, T., Fujishiro, M., Iijima, K., Inoue, H., Kawai, T., Kinoshita, Y., Miwa, H., Mukaisho, K. I., Murakami, K., Seto, Y., Tajiri, H., Bhatia, S., Choi, M. G., Fitzgerald, R. C., Fock, K. M., … Malfertheiner, P. (2022). Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut, 71(8), 1488-1514.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209-249.

Wu, M., Feng, S., Qian, M., Wang, S., & Zhang, K. (2022). Helicobacter pylori Infection Combined with OLGA and OLGIM Staging Systems for Risk Assessment of Gastric Cancer: A Retrospective Study in Eastern China. Risk management and healthcare policy, 15, 2243-2255.

Mansour-Ghanaei, F., Joukar, F., Yeganeh, S., Sadeghi, M., Daryakar, A., & Sepehrimanesh, M. (2022). OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications. The Turkish journal of gastroenterology, 33(2), 95-102.

Mera, R. M., Bravo, L. E., Camargo, M. C., Bravo, J. C., Delgado, A. G., Romero-Gallo, J., Yepez, M. C., Realpe, J. L., Schneider, B. G., Morgan, D. R., Peek, R. M., Jr, Correa, P., Wilson, K. T., & Piazuelo, M. B. (2018). Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut, 67(7), 1239-1246.

Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., Cree, I. A., & WHO Classification of Tumours Editorial Board (2020). The 2019 WHO classification of tumours of the digestive system. Histopathology, 76(2), 182-188.

Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J. M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., Rugge, M., Suerbaum, S., Tilg, H., Sugano, K., El-Omar, E. M., & European Helicobacter and Microbiota Study group (2022). Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut, 71(9), 1724-1762.



How to Cite

Stepanov YM, Haidar YA, Maltseva OA. Chronic atrophic gastritis as a precancer: the evolution of ideas from the Sydney consensus to Maastricht VI. Pathologia [Internet]. 2023Jan.27 [cited 2024Apr.16];19(3):227-35. Available from: